0 47

Cited 1 times in

Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial

DC FieldValueLanguage
dc.contributor.author김효송-
dc.contributor.author라선영-
dc.contributor.author정민규-
dc.contributor.author정현철-
dc.date.accessioned2019-01-15T16:52:20Z-
dc.date.available2019-01-15T16:52:20Z-
dc.date.issued2018-
dc.identifier.issn1078-0432-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/166693-
dc.description.abstractPurpose: The oxaliplatin plus S-1 and cisplatin plus S-1 regimens are interchangeably used in the management of advanced gastric cancer. The previously reported G-intestinal (G1) and G-diffuse (G2) intrinsic gene expression signatures showed promise for stratifying patients according to their tumor sensitivity to oxaliplatin or cisplatin.Experimental Design: The proof-of-concept, multicenter, open-label phase II "3G" trial was done to prospectively evaluate the feasibility and efficacy of using genomic classifiers to tailor treatment in gastric cancer. Patients' tumors were classified as "G1" or "G2" using a nearest-prediction template method, or "G3" (unclear assignment) when FDR ≥ 0.05. The first 30 patients in the "G1" cohort were assigned oxaliplatin plus S-1 (SOX) chemotherapy; thereafter, subsequently recruited "G1" patients were treated with cisplatin plus S-1 (SP) chemotherapy. "G2" patients and "G3" patients were treated with SP and SOX chemotherapy, respectively.Results: A total of 48, 21, and 12 patients, respectively, were given "G1," "G2," and "G3" genomic assignments. Median turnaround time was 7 days (IQR, 5-9). Response rates were 44.8%, 8.3%, 26.7%, and 55.6% for the "G1-SOX," "G1-SP," "G2," "G3" cohorts, respectively; and was higher in G1 patients treated with SOX compared with SP (P = 0.033). Exploratory analyses using the genomic classifier of Lei and colleagues validated the utility of the metabolic signature as a biomarker for predicting benefit from chemotherapy (log-rank P = 0.004 for PFS), whereas the Asian Cancer Research Group classifier did not demonstrate any predictive value.Conclusions: This bench-to-bedside effort establishes a reasonable turnaround time for gene expression profiling and possible utility of genomic classifiers in gastric cancer treatment stratification.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherAmerican Association for Cancer Research-
dc.relation.isPartOfClinical Cancer Research-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleReal-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorWei Peng Yong-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorIain Bee-Huat Tan-
dc.contributor.googleauthorSu-Pin Choo-
dc.contributor.googleauthorNicholas L. Syn-
dc.contributor.googleauthorVivien Koh-
dc.contributor.googleauthorShi-Hui Tan-
dc.contributor.googleauthorBernadette Reyna Asuncion-
dc.contributor.googleauthorRaghav Sundar-
dc.contributor.googleauthorJimmy Bok-Yan So-
dc.contributor.googleauthorAsim Shabbir-
dc.contributor.googleauthorChee-Seng Tan-
dc.contributor.googleauthorHyo-Song Kim-
dc.contributor.googleauthorMinkyu Jung-
dc.contributor.googleauthorHyun Cheol Chung-
dc.contributor.googleauthorMatthew C.H. Ng-
dc.contributor.googleauthorDavid Wai-Meng Tai-
dc.contributor.googleauthorMing-Hui Lee-
dc.contributor.googleauthorJeanie Wu-
dc.contributor.googleauthorKhay Guan Yeoh-
dc.contributor.googleauthorPatrick Tan-
dc.identifier.doi10.1158/1078-0432.CCR-18-0193-
dc.contributor.localIdA01202-
dc.contributor.localIdA01316-
dc.contributor.localIdA01316-
dc.contributor.localIdA03606-
dc.contributor.localIdA03606-
dc.contributor.localIdA03773-
dc.contributor.localIdA03773-
dc.relation.journalcodeJ00564-
dc.identifier.pmid30045931-
dc.identifier.urlhttp://clincancerres.aacrjournals.org/content/24/21/5272.long-
dc.contributor.alternativeNameKim, Hyo Song-
dc.contributor.affiliatedAuthor김효송-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor정민규-
dc.contributor.affiliatedAuthor정민규-
dc.contributor.affiliatedAuthor정현철-
dc.contributor.affiliatedAuthor정현철-
dc.citation.volume24-
dc.citation.number21-
dc.citation.startPage5272-
dc.citation.endPage5281-
dc.identifier.bibliographicCitationClinical Cancer Research, Vol.24(21) : 5272-5281, 2018-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.